Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.
The bioavailability of didanosine at 180 mg/m(2) once daily was compared to that at 90 mg/m(2) twice daily in 24 children with advanced human immunodeficiency virus infection. Children were studied at steady state using optimal sampling and prior pharmacokinetic parameter estimates. Relative bioavailability was 0. 95 +/- 0.49, supporting the potential clinical adequacy of once-daily dosing.
Abreu
T
T
Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Plaisance
K
K
Rexroad
V
V
Nogueira
S
S
Oliveira
R H
RH
Evangelista
L A
LA
Rangel
R
R
Silva
I S
IS
Knupp
C
C
Lambert
J S
JS
D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D002648:Child; D002675:Child, Preschool; D016049:Didanosine / Q000493:pharmacokinetics*; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans
D019380:Anti-HIV Agents; D016049:Didanosine